Beneficial effects of olmesartan, a novel angiotensin II receptor type 1 antagonist, upon acute autoimmune myocarditis

Molecular and Cellular Biochemistry

Volumn 259, Issue 1-2, 2004, Pages 217-222

  Nimata, Masaomi ^a   Kishimoto, Chiharu ^a   Yuan, Zuyi ^a   Shioji, Keisuke ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Angiotensin II receptor type 1 antagonist; Cytokine; Myocarditis

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CYTOKINE; INTERLEUKIN 1BETA; OLMESARTAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; BLOOD PRESSURE REGULATION; BODY WEIGHT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG MECHANISM; HEART HEMODYNAMICS; HEART PROTECTION; HEART WEIGHT; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; MICROSCOPY; MYOCARDITIS; NONHUMAN; PERICARDIAL EFFUSION; RAT; SCORING SYSTEM;

ADMINISTRATION, ORAL; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; AUTOIMMUNE DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; IMIDAZOLES; INTERLEUKIN-1; MALE; MYOCARDITIS; MYOCARDIUM; MYOSINS; RATS; RATS, INBRED LEW; RECEPTOR, ANGIOTENSIN, TYPE 1; SWINE; TETRAZOLES;

EID: 1942506579     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:MCBI.0000021379.82282.53     Document Type: Article

References (22)

1. Kawai C: From myocarditis to cardiomyopathy: Mechanisms of inflammation and cell death. Circulation 99: 1091-1100, 1999
2. Kodama M, Matsumoto Y, Fujiwara M, Masani F, Izumi T, Shibata A: A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol 57: 250-262, 1990
3. Stuehr DJ, Marletta MA: Induction of nitrite/nitrate synthesis in murine macrophages by BCG infection, lymphokines, or interferon-γ. J Immunol 139: 518-525, 1987
4. Adams V, Nehrhoff B, Spate U, Linke A, Schulze PC, Baur A, Gielen S, Hambrecht R, Schuler G: Induction of iNOS expression in skeletal muscle by IL-1beta and NF-kappaB activation: An in vitro and in vivo Study. Cardiovasc Res 54: 95-104, 2002
5. Song W, Lu X, Feng Q: Tumor necrosis factor-alpha induces apoptosis via inducible nitric oxide synthase in neonatal mouse cardiomyocytes. Cardiovasc Res 45: 595-602, 2000
6. Mulligan MS, Hevel JM, Marletta MA, Ward PA: Tissue injury caused by deposition of immune complexes in L-arginine dependent. Proc Natl Acad Sci USA 88: 6338-6342, 1991
7. Ishiyama S, Hiroe M, Nishikawa T, Abe S, Shimojo T, Ito H, Ozasa S, Yamakawa K, Matsuzaki M, Mohammed MU, Nakazawa H, Kasajima T, Marumo F: Nitric oxide contributes the progression of myocardial damage in experimental autoimmune myocarditis in rats. Circulation 95: 489-496, 1997
8. Mungrue IN, Gros R, Pirani A, Azard A, Csont T, Schulz R, Butany J, Stewart DJ, Husain M: Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Invest 109: 735-743, 2002
9. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL: Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 257: 387-389, 1992
10. Furukawa T, Kobuke K, Matsumori A: Role of cytokines in autoimmune myocarditis and cardiomyopathy. Autoimmunity 34: 165-168, 2001
11. Iwasaki A, Matsumori A, Yamada T, Shioi T, Wang W, Ono K, Nishio R, Okada M, Sasayama S: Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis: A possible mechanism through inhibition of nitric oxide production. J Am Coll Cardiol 33: 1400-1407, 1999
12. Mollnau H, Wendt M, Szöcs K, Lassèque B, Schulz E, Oelze M, Li H, Bodenschatz M, August M, Kleschyov AL, Tsilimingas N, Walter U, Förstermann U, Meinertz T, Griendling K, Münzel T: Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 90: e58-e65, 2002
13. Warnholtz A, Nickering G, Schultz E, Macharzina R, Bräsen JH, Skatchkov M, Heiter T, Stasch JP, Griendling KK, Harrison DG, Bö hm M, Meinertz T, Münzel T: Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis. Evidence for involvement of the renin-angiotensin system. Circulation 99: 2027-2033, 1999
14. Burnier M: Angiotensin II type 1 receptor blockers. Circulation 103: 904-912, 2001
15. Shioji K, Kishimoto C, Sasayama S: Fc receptor-mediated inhibitory effect of immunoglobulin therapy on autoimmune giant cell myocarditis: Concomitant suppression of the expression of dendritic cells. Circ Res 89: 540-546, 2001
16. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S: Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 72: 561-566, 1994
17. Shioi T, Matsumori A, Sasayama S: Persistent expression of cytokines in the chronic stage of viral myocarditis in mice. Circulation 94: 2930-2937, 1996
18. Kubota T, McTiernan CF, Frye CS, Demetris AJ, Feldman AM: Cardiac-specific overexpression of tumor necrosis factor-alpha causes lethal myocarditis in transgenic mice. J Card Fail 3: 117-124, 1997
19. Lane JR, Neumann DA, Lafond-Walker A, Herskowitz A, Rose NR: Interleukin 1 or tumor necrosis factor can promote Coxsackie virus-induced myocarditis in resistant B10.A mice. J Exp Med 175: 1123-1123, 1992
20. Kishimoto C, Takada H, Kawamata H, Umatake M, Ochiai H: Immunoglobulin treatment prevents congestive heart failure in murine encephalomyocarditis viral myocarditis associated with reduction of inflammatory cytokines. J Pharmacol Exp Ther 299: 645-651, 2001
21. Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN: Augumented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to an angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) study group. Circulation 99: 2658-2664, 1999
22. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure. Randomised trial. The Losartan Heart Failure Survival Study ELITE II. Lancet 355: 1582-1587, 2000